Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAâ„¢ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis
AD is one of the most common chronic inflammatory diseases with prevalence rates of up to 5% in adults and approximately 25% in children.
Read More
